RC
GRCE

Rangeley Capital’s Grace Therapeutics GRCE Stock Holding History

Rangeley Capital’s Portfolio GRCE Stock Details GRCE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$59K Buy
+26,000
New +$71.9K 0.05% 157

Other funds holding GRCE

Cerity Partners
Cerity Partners New York $82.7B AUM 28.53% 1-Year Est. Return
EP
Eversept Partners New York $1.93B AUM 160.8% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Citadel Advisors
Citadel Advisors Miami, Florida $875B AUM 40.89% 1-Year Est. Return
MS
Maven Securities St Helier, Jersey $5.06B AUM 59.27% 1-Year Est. Return
BC
Birchview Capital Burlington, Vermont $214M AUM 185.33% 1-Year Est. Return
CF
Cantor Fitzgerald New York $9.31B AUM 73.66% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return
Jane Street
Jane Street New York $1.21T AUM 78.12% 1-Year Est. Return

Rangeley Capital's GRCE Position: Q2 2026 in Review

Rangeley Capital opened a new position in Grace Therapeutics (GRCE) in Q2 2026: 26,000 shares worth $59K. The stake represents 0.05% of the portfolio and ranks #157 among its holdings.

33 funds tracked by Wall St. Rank hold GRCE as of Q2 2026.

  • Rangeley Capital held 26,000 shares of Grace Therapeutics worth $59K as of Q2 2026.
  • Grace Therapeutics was a new Rangeley Capital position in Q2 2026.
  • Grace Therapeutics made up 0.05% of Rangeley Capital's portfolio in Q2 2026, its #157 holding.
  • 33 funds tracked by Wall St. Rank held Grace Therapeutics as of Q2 2026.

Based on Rangeley Capital's 13F filing for Q2 2026, filed 14 Aug 2026.